Lomustine_13010-47-4_DataSheet_MedChemExpress

合集下载

Naglazyme（galsulfase）（抗生物）商品说明书

Naglazyme® (galsulfase)(Intravenous)Document Number: MH-0084 Last Review Date: 02/01/2022Date of Origin: 11/28/2011Dates Reviewed: 12/2011, 02/2013, 02/2014, 12/2014, 10/2015, 10/2016, 10/2017, 10/2018, 02/2019,02/2020, 02/2021, 02/2022I.Length of AuthorizationCoverage will be provided for 12 months and may be renewed.II.Dosing LimitsA.Quantity Limit (max daily dose) [NDC Unit]:•Naglazyme 5 mg vial: 23 vials per 7 daysB.Max Units (per dose and over time) [HCPCS Unit]:•115 billable units every 7 daysIII.Initial Approval Criteria 1Coverage is provided in the following conditions:•Patient is at least 5 years of age; AND•Documented baseline 12-minute walk test (12-MWT), 3-minute stair climb test (3-MSCT), and/or pulmonary function tests (e.g., FEV1, etc.); AND•Documented baseline value for urinary glycosaminoglycan (uGAG); ANDMucopolysaccharidosis VI (MPS VI, Maroteaux-Lamy syndrome) † Ф1,4,5•Patient has a definitive diagnosis of MPS VI as confirmed by the following:o Detection of pathogenic mutations in the ARSB gene by molecular genetic testing; ORo Arylsulfatase B (ASB) enzyme activity of <10% of the lower limit of normal in cultured fibroblasts or isolated leukocytes; AND▪Patient has normal enzyme activity of a different sulfatase (excluding patients with Multiple Sulfatase Deficiency [MSD]); AND▪Patient has an elevated urinary glycosaminoglycan (uGAG) level (i.e. dermatan sulfate or chondroitin sulfate) defined as being above the upper limit of normal bythe reference laboratory†FDA-approved indication(s); ‡Compendia recommended indication(s); ФOrphan DrugIV.Renewal Criteria 1,4,5Coverage can be renewed based on the following criteria:•Patient continues to meet indication-specific relevant criteria such as concomitant therapy requirements (not including prerequisite therapy), performance status, etc. identified insection III; AND•Absence of unacceptable toxicity from the drug. Examples of unacceptable toxicity include: anaphylaxis and hypersensitivity reactions, immune-mediated reactions, acute respiratorycomplications associated with administration, acute cardiorespiratory failure, severeinfusion reactions, spinal or cervical cord compression, etc.; AND•Disease response with treatment as defined by improvement or stability from pre-treatment baseline by the following:o Reduction in uGAG levels; AND▪Improvement in or stability of 12-minute walk test compared (12-MWT); OR▪Improvement in or stability of 3-minute stair climb test (3-MSCT); OR▪Improvement in or stability of pulmonary function testing (e.g., FEV1, etc.)V.Dosage/Administration 1Indication DoseMucopolysaccharidosis VI(MPS VI, Maroteaux-Lamy Syndrome) 1 mg/kg administered as an intravenous (IV) infusion oncea weekVI.Billing Code/Availability InformationHCPCS Code:•J1458 – Injection, galsulfase, 1 mg; 1 billable unit = 1 mgNDC:•Naglazyme 5 mg per 5 mL solution; single-use vial: 68135-0020-xxVII.References1.Naglazyme [package insert]. Novato, CA; BioMarin Pharmaceutical Inc.; December 2019.Accessed January 2022.2.Giugliani R, Harmatz P, Wraith JE. Management guidelines for mucopolysaccharidosis VI.Pediatrics. 2007 Aug;120(2):405-18.3.Giugliani R, Federhen A, Rojas MV, et al. Mucopolysaccharidosis I, II, and VI: Brief reviewand guidelines for treatment. Genet Mol Biol. 2010 Oct;33(4):589-604. Epub 2010 Dec 1.4.Vairo F, Federhen A, Baldo G, et al. Diagnostic and treatment strategies inmucopolysaccharidosis VI. Appl Clin Genet. 2015 Oct 30;8:245-55.5.Valaannopoulos V, Nicely H, Harmatz P, et al. Mucopolysaccharidosis VI. Orphanet J RareDis. 2010; 5: 5.6.Harmatz P, Giugliani R, Schwartz I, et al. Enzyme replacement therapy formucopolysaccharidosis VI: a phase 3, randomized, double-blind, placebo-controlled,multinational study of recombinant human N-acetylgalactosamine 4-sulfatase(recombinant human arylsulfatase B or rhASB) and follow-on, open-label extension study. JPediatr. 2006 Apr;148(4):533-539.Appendix 1 – Covered Diagnosis CodesICD-10 ICD-10 DescriptionE76.29 Other mucopolysaccharidosesAppendix 2 – Centers for Medicare and Medicaid Services (CMS)Medicare coverage for outpatient (Part B) drugs is outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals. In addition, National CoverageDetermination (NCD), Local Coverage Determinations (LCDs), and Local Coverage Articles (LCAs) may exist and compliance with these policies is required where applicable. They can be found at: https:///medicare-coverage-database/search.aspx. Additional indications may be covered at the discretion of the health plan.Medicare Part B Covered Diagnosis Codes (applicable to existing NCD/LCD/LCA): N/AMedicare Part B Administrative Contractor (MAC) JurisdictionsJurisdiction Applicable State/US Territory ContractorE (1) CA, HI, NV, AS, GU, CNMI Noridian Healthcare Solutions, LLCF (2 & 3) AK, WA, OR, ID, ND, SD, MT, WY, UT, AZ Noridian Healthcare Solutions, LLC5 KS, NE, IA, MO Wisconsin Physicians Service Insurance Corp (WPS)6 MN, WI, IL National Government Services, Inc. (NGS)H (4 & 7) LA, AR, MS, TX, OK, CO, NM Novitas Solutions, Inc.8 MI, IN Wisconsin Physicians Service Insurance Corp (WPS) N (9) FL, PR, VI First Coast Service Options, Inc.J (10) TN, GA, AL Palmetto GBA, LLCM (11) NC, SC, WV, VA (excluding below) Palmetto GBA, LLCNovitas Solutions, Inc.L (12) DE, MD, PA, NJ, DC (includes Arlington &Fairfax counties and the city of Alexandria in VA)K (13 & 14) NY, CT, MA, RI, VT, ME, NH National Government Services, Inc. (NGS)15 KY, OH CGS Administrators, LLC。

HSF1A_DataSheet_MedChemExpress

Inhibitors, Agonists, Screening Libraries Data SheetBIOLOGICAL ACTIVITY:HSF1A is a cell–permeable activator of heat shock transcription factor 1 (HSF1).IC50 & Target: HSF1[1]In Vitro: HSF1A protects cells from stress–induced apoptosis, binds TRiC subunits and inhibits TRiC activity without perturbation of ATP hydrolysis. Genetic inactivation or depletion of the TRiC complex results in human HSF1 activation and HSF1A inhibits the direct interaction between purified TRiC and HSF1 in vitro. Moreover, fluorescence anisotropy experiments using FITC coupled to HSF1A demonstrates that HSF1A–FITC binds to a purified Tcp1 subunit of TRiC with an affinity of approximately 600 nM. This is validated qualitatively via titration of purified Tcp1 into binding reactions containing 500 nM Biotin or HSF1A–Biotin [1]. Quantification bycounting the number of cell containing aggregates as a function of the total number of cells reveals that at HSF1A concentrations as low as 2 μM, a reduced number of aggregate–containing cells are observed. The fraction of cells containing aggregates continued to decrease in a dose–dependent manner such that pretreatment with 12 μM HSF1A resulta in ~20% of the cells exhibiting aggregates visible by fluorescence microscopy [2].In Vivo: HSF1A enhances HSF1 activity, stabilizes HSF1 expression and minimizes Doxorubicin (DOX)–induced cardiac damage. WKY rats are challenged with DOX (accumulated dose: 30 mg/kgw), and DOX combined with HSF1A (100 mg/kgw/day). Supplementation with HSF1A significantly elevates cardiac functions back to the levels of the control group. HSF1A has been shown to stimulate human HSF1 nuclear translocation, elevate protein chaperone expression and ameliorate protein misfolding and cell death in aneurodegenerative disease model. The echocardiographic results show that HSF1A also alleviates DOX–induced failures in cardiac function [3].PROTOCOL (Extracted from published papers and Only for reference)Kinase Assay:[1]Protein extracts are generated from mammalian, yeast and E. coli cultures using biotin–binding buffer (20 mM HEPES,5 mM MgCl 2, 1 mM EDTA, 100 mM KCl, 0.03% NP–40) supplemented with 1% Trition–X100 and protease inhibitors. Approximately 0.5mg of protein extract is incubated with 100 μM HSF1A–Biotin for 4 h at 4°C and HSF1A–Biotin associated proteins captured by with NeutrAvidin Agarose Resin. After washing in biotin binding buffer proteins are eluted using 50 μL biotin elution buffer (100 mM Tris,150 mM NaCl, 0.1 mM EDTA, 2 mM D–biotin), resolved on a 4–20% SDS–PAGE, and immunoblotted. For purified TRiC and Hsp70analyses, 5 nM protein is incubated in biotin–binding buffer+0.5% Triton X–100 with 100 μM biotin or 100 μM HSF1A–Biotin for 4 h at 4°C and captured with NeutrAvidin Resin. For NiNTA purified yeast Tcp1, different concentrations of Tcp1 0.5 μM, 1 mM, 2 mM, 3 mM and 4 mM in 25 mM Hepes pH 7.5, 150 mM NaCl are incubated with 0.5 μM Biotin or HSF1A–Biotin for 4 h at 4°C and captured with NeutrAvidin Resin [1].Cell Assay:[2]PC12 cells seeded into a 96–well plate (5×104 cells/well) are treated with increasing concentrations of HSF1A (2, 4, 8 andProduct Name:HSF1A Cat. No.:HY-103000CAS No.:1196723-93-9Molecular Formula:C21H19N3O2S2Molecular Weight:409.52Target:HSP Pathway:Cell Cycle/DNA Damage; Metabolic Enzyme/Protease Solubility:DMSO: ≥ 150 mg/mL12 μM) for 15 h, at which time httQ74–GFP expression is stimulated by incubation in the presence of 1 μg/mL Doxycycline for 5 d. Cell viability is assessed via the XTT viability assay[2].Animal Administration:[3]Rat[3]Ten–week–old Wistar Kyoto rats (WKY) are used. The rats are housed at a constant temperature (22°C) on a 12–h light/dark cycle with food and tap water. The animals are arranged into three groups: WKY rats (the control group), DOX rats and DOX rats treated with HSF1A. Each group contain five animals. The DOX group is injected with DOX (5 mg/kg) for 6 consecutive weeks intraperitoneal injection to achieve a cumulative dose of 30 mg/kg, which has been well documented to achieve cardiotoxicity. The small molecular HSF1 activator HSF1A (100 mg/kg/day) is injected intraperitoneally.References:[1]. Neef DW, et al. A direct regulatory interaction between chaperonin TRiC and stress–responsive transcription factor HSF1. Cell Rep. 2014 Nov 6;9(3):955–66.[2]. Neef DW, et al. Modulation of heat shock transcription factor 1 as a therapeutic target for small molecule intervention in neurodegenerative disease. PLoS Biol. 2010 Jan 19;8(1):e1000291.[3]. Huang CY, et al. Doxorubicin attenuates CHIP–guarded HSF1 nuclear translocation and protein stability to trigger IGF–IIR–dependent cardiomyocyte death. Cell Death Dis. 2016 Nov 3;7(11):e2455.Caution: Product has not been fully validated for medical applications. For research use only.Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA。

ACCUSPIN系统-Histopaque 1077产品说明书

Technical BulletinACCUSPIN™ System – Histopaque ® 1077Catalog Numbers A6929, A7054, and A0561Product DescriptionACCUSPIN System-Histopaque -1077products are intended for use in the isolation of lymphocytes and other mononuclear cells. The separation medium, Histopaque-1077, is a sterile-filtered, endotoxin tested solution of polysucrose and sodium diatrizoate, adjusted to a density of 1.077 g/mL. The ACCUSPIN tube is specially designed with two chambers separated by a porous high density polyethylene barrier (frit).Separation of lymphocytes and other mononuclear cells from whole blood and bone marrow using density gradientseparation media is based on a published method.1 Histopaque-1077 is suitable for human lymphocyte antigen (HLA) typing 2 and as the initial isolation step prior toenumeration of T, B, and ‘null’ lymphocytes.3 It may also be employed in the preparation of pure lymphocyte suspensions for cell culture and cytotoxicity assays.4ACCUSPIN System-Histopaque-1077 products consist of radiation sterilized polypropylene tubes fitted with a highdensity polyethylene frit and aseptically filled with Histopaque-1077.Histopaque-1077 is a sterile-filtered solution of polysucrose, 57 g/L, and sodium diatrizoate, 90 g/L.Density: 1.076–1.078 g/mL Endotoxin: 0.3 EU/mL pH: 8.8–9.0ACCUSPIN System-Histopaque-1077Catalog No. A692940 × 3 mLEach tube contains 3 mL ofHistopaque 1077-1 and will separate 3-6 mL of anticoagulated blood Catalog No. A7054 12 × 15 mLCatalog No. A0561100 × 15 mLEach tube contains 15 mL ofHistopaque 1077-1 and will separate 15-30 mL of anticoagulated bloodReagents and Equipment Required but Not ProvidedCentrifuge (swinging bucket rotor)capable of generating 100 to 1,000 g Centrifuge tubes for washing mononuclear cellsIsotonic phosphate buffered saline solution or appropriate cell culture mediumPrecautions and DisclaimerFor R&D use only. Not for drug, household, or other uses. Please consult the Safety Data Sheet for information regarding hazards and safe handling practices.Preparation InstructionsSpecimen Collection - Collect blood in preservative-free anticoagulant (EDTA or heparin) or use defibrinated blood. For best results, blood should be processed within 2 hours.On occasion, it may be necessary to dilute the blood sample 3 to 5-fold, depending on absolute cell numbers. A similar volume of prediluted blood may be used or the blood sample may be diluted directly in upper chamber of the ACCUSPIN tube (seeProcedure, step 3). This is appropriate for specimens with hematocrits above normal.Storage/StabilityStore the products at 2–8 C.Histopaque-1077 has an expiration period of 3 years. Reagent label bears expiration date.ProcedureAnticoagulated blood can be added to the top chamber of the tube without risk of mixing with the Histopaque-1077 in the lowerchamber under the frit. On centrifugation the whole blood migrates through the frit to contact with the Histopaque-1077. The elements of greater density displace a volume of Histopaque-1077 above the frit giving a clear separation of the bloodcomponents. The erythrocytes aggregate and the granulocytes become slightly hypertonic, increasing their sedimentation rate, resulting in pelleting at the bottom of the ACCUSPIN Tube. Lymphocytes and other mononuclear cells, e.g., monocytes, remain at the plasma/Histopaque-1077 interface. This dense band of mononuclear cells may be collected by pouring off the contents of the upper chamber or by means of a pipette. Erythrocyte contamination is avoided due to the barrier between the chambers.Most extraneous platelets are removed by low speed centrifugation during the washing steps.1. Bring desired number of tubes to roomtemperature. If Histopaque-1077 isabove the frit prior to use, centrifuge at 1,000 g for 30 seconds at room temperature.Note: Failure to bring ACCUSPIN System-Histopaque-1077 to room temperature may cause limited recovery of mononuclear cells. 2. Label tube(s).3. Freely pour the blood sample into theupper chamber of each ACCUSPIN System-Histopaque-1077 tube.a. Use 3–6 mL of whole blood withACCUSPIN System-Histopaque-1077 tubes, Catalog No. A6929. b. Use 15–30 mL of whole blood withACCUSPIN System-Histopaque-1077 tubes, Catalog Nos. A7054 or A0561. Note: Use of volumes of prediluted or whole blood other than those recommended may result in decreased recovery.4. Centrifuge at 1,000 g for 10 minutes atroom temperature or centrifuge at 800 g for 15 minutes at roomtemperature. Centrifugation at lower temperatures, such as 4 C, may result in cell clumping and poor recovery.Note: If platelet contamination is a concern, add the mononuclear cells to a 4-20% sucrose gradient that has been layered over Histopaque-1077.Centrifuge at 1,000 × g for 10 minutes at room temperature. The platelets will pellet at the bottom, while themononuclear cells will migrate to the Histopaque-1077 layer.5. After centrifugation, carefully aspiratethe plasma layer with a Pasteur pipette to within 0.5 cm of the opaque interface containing mononuclear cells. Properly dispose of the plasma layer.Note: Failure to remove the excesssupernatant may result in contamination of the mononuclear band with plasma proteins.6. Carefully transfer the opaque interfacewith a Pasteur pipette into a clean conical centrifuge tube.Note: Removal of Histopaque-1077 with the mononuclear band increasesgranulocyte contamination from residual granulocytes, which may remain at the mononuclear interface.7. Wash the cells by adding 10 mL ofisotonic phosphate buffered saline solution or appropriate cell culture medium and mix by gently drawing in and out of a Pasteur pipette. 8. Centrifuge at 250 g for 10 minutes. 9. Aspirate the supernatant and discard. 10. Resuspend cell pellet with 5 mL ofisotonic phosphate buffered saline solution or appropriate cell culture medium and mix by gently drawing in and out of a Pasteur pipette.11. Centrifuge at 250 g for 10 minutes. 12. Repeat steps 9, 10, and 11, discardsupernatant and resuspend cell pellet in 0.5 mL of isotonic phosphate buffered saline solution or appropriate cell culture medium. Erythrocytes and granulocytes should pellet to the bottom of the ACCUSPIN tube. Mononuclear cells should band at the interface between the Histopaque-1077 and the plasma. If observed results vary from expected results, please contact Sigma-Aldrich Technical Service for assistance.References1. Boyum, A., Separation of leukocytesfrom blood and bone marrow. Scand. J. Clin. Lab. Invest ., 21 (Suppl 97), 77 (1968).2. Amos, D.B., and Pool, P., “HLA typing” inManual of Clinical Immunology, Rose, N.R., and Friedman, H., eds., American Society for Microbiology, (Washington, DC: 1976) pp. 797-804.3. Winchester, R.J., and Ross, G., “Methodsfor enumerating lymphocyte populations” in Manual of Clinical Immunology, Rose, N.R., and Friedman, H. eds., American Society for Microbiology, (Washington, DC: 1976) pp. 64-76.4. Thorsby, E., and Bratlie, A., “A rapidmethod for preparation of pure lymphocyte suspensions.”Histocompatibility Testing, Terasaki, P.I., ed., 665-666 (1970).The life science business of Merck operates as MilliporeSigma in the U.S. and Canada.Merck, Sigma-Aldrich, ACCUSPIN, and Histopaque are trademarks of Merck KGaA, Darmstadt, Germany or its affiliates. All other trademarks are the property of their respective owners. Detailed information on trademarks is available via publicly accessible resources.© 2022 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.NoticeWe provide information and advice to our customers on application technologies and regulatory matters to the best of our knowledge and ability, but without obligation or liability. Existing laws and regulations are to be observed in all cases by our customers. This also applies in respect to any rights of third parties. Our information and advice do not relieve our customers of their own responsibility for checking the suitability of our products for the envisaged purpose.The information in this document is subject to change without notice and should not be construed as a commitment by the manufacturing or selling entity, or an affiliate. We assume no responsibility for any errors that may appear in this document.Contact InformationFor the location of the office nearest you, go to /offices .Technical ServiceVisit the tech service page on our web site at /techservice .Standard WarrantyThe applicable warranty for the products listed in this publication may be found at /terms .A0561 Technical Bulletin Rev 06/2022。

3_种常用碳青霉烯类抗生素血药浓度UPLC-MS

3种常用碳青霉烯类抗生素血药浓度UPLC-MS/MS检测方法的建立Δ秦怡1＊，张瑞霞2，吕雅瑶2，翁莉莉1，张弋2 #（1.天津医科大学一中心临床学院，天津　300192；2.天津市第一中心医院药学部，天津　300192）中图分类号 R917；R978.1文献标志码 A 文章编号 1001-0408（2024）03-0343-05DOI 10.6039/j.issn.1001-0408.2024.03.14摘要目的建立3种临床常用碳青霉烯类抗生素——厄他培南（ETP）、亚胺培南（IPM）、美罗培南（MEM）血药浓度检测的超高效液相色谱-质谱联用（UPLC-MS/MS）法。

方法血浆样品经甲醇沉淀蛋白后，以3种抗生素的稳定性同位素（ETP-D4、IPM-D4、MEM-D6）为内标，采用ACQUITY UPLC BEH C18（2.1 mm×50 mm，1.7μm）色谱柱分离；流动相为98%乙腈+2%水+0.1%甲酸和98%水+2%乙腈+0.1%甲酸，梯度洗脱；流速为0.3 mL/min；柱温为40 ℃；采用正离子、多反应监测模式进行扫描分析。

结果该方法专属性良好，在ETP、IPM、MEM 0.2～200、0.1～100、0.1～100μg/mL范围内线性良好（r2≥0.993），批内、批间精密度和准确度良好（RE均≤5.14%，RSD均≤11.15%），基质效应、提取回收率较一致（RSD≤12.99%）。

结论本实验建立了一种可以同时定量ETP、IPM、MEM血药浓度的UPLC-MS/MS法，该方法样品前处理简单、检测时间短、所需样品量少，可满足临床需求。

关键词碳青霉烯类抗生素；超高效液相色谱-质谱联用；血药浓度；厄他培南；亚胺培南；美罗培南Establishment of UPLC-MS/MS method for the determination of plasma concentration of three common carbapenem antibioticsQIN　Yi1，ZHANG　Ruixia2，LYU　Yayao2，WENG　Lili1，ZHANG　Yi2（1. First Central Clinical College of Tianjin Medical University，Tianjin 300192，China；2. Dept. of Pharmacy，Tianjin First Central Clinical Hospital，Tianjin 300192， China）ABSTRACT OBJECTIVE To establish a UPLC-MS/MS method for the determination of plasma concentration of three carbapenem antibiotics，i.e. ertapenem （ETP），imipenem （IPM）and meropenem （MEM）.METHODS After protein precipitation with methanol，the plasma samples were separated by ACQUITY UPLC BEH C18column （2.1mm×50mm，1.7μm）using stable isotopes of three antibiotics （ETP-D4，IPM-D4，MEM-D6）as the internal standard. The mobile phases were 98%acetonitrile +2% water +0.1%formic acid and 98%water +2%acetonitrile +0.1%formic acid，by gradient elution. The flow rate was 0.3mL/min and the column temperature was 40 ℃. Scanning analysis was performed in the positive ion and multiple reaction monitoring mode. RESULTS The method had good specificity，good linearity （r2≥0.993）in the range of 0.2-200，0.1-100and 0.1-100μg/mL of ETP，IPM and MEM，and good intra-batch and inter-batch precision and accuracy （all RE≤5.14%，all RSD≤11.15%），the matrix effect and extraction recovery were consistent （RSD≤12.99%）. CONCLUSIONS This study establishes the UPLC-MS/MS method to simultaneously quantify the plasma concentration of ETP，IPM and MEM. The method has the advantages of simple pretreatment， short detection time and small sample quantity to meet clinical requirement.KEYWORDS carbapenem antibiotics； UPLC-MS/MS； plasma concentration； ertapenem； imipenem； meropenem碳青霉烯类抗生素具有抗菌谱广、抗菌活性强、耐药率低的特点，已成为治疗重症感染的主要选择。

CFDA SE (细胞增殖示踪荧光探针) 说明书

CFDA SE (细胞增殖示踪荧光探针) 产品编号产品名称包装C1031 CFDA SE (细胞增殖示踪荧光探针) 5mg产品简介：CFDA SE 的全称为Carboxyfluorescein diacetate, succinimidyl ester ，是一种近年来被广泛应用的细胞增殖检测用荧光探针，也可以用于细胞的荧光示踪。

基于CFDA SE 荧光标记的细胞增殖检测和[3H]-thymidine 掺入、BrdU 标记获得的检测结果完全一致，但同时可以提供更多的细胞增殖信息。

使用CFDA SE 检测可以提供整个细胞群中有多少比例的细胞分裂了1次、2次或更多次数，同时如果和其它荧光探针联用，可以获取不同分裂次数细胞的其它相关信息。

CFDA-SE 的分子式为C 29H 19NO 11，分子量为557.47，CAS number 为150347-59-4。

CFDA SE 可以通透细胞膜，进入细胞后可以被细胞内的酯酶(esterase)催化分解成CFSE ，CFSE 可以偶发性地(spontaneously)并不可逆地和细胞内蛋白的Lysine 残基或其它氨基发生结合反应，并标记这些蛋白。

在加入荧光探针CFDA SE 后大约24小时，即可充分标记细胞。

被CFDA SE 标记的非分裂细胞的荧光非常稳定，稳定标记的时间可达数个月。

CFDA SE 标记细胞的荧光非常均一，比以前使用的其它细胞示踪荧光探针例如PKH26的荧光更加均一，并且分裂后的子代细胞的荧光分配也更均匀。

由于CFDA SE 标记细胞的荧光非常均匀和稳定，每分裂一次子代细胞的荧光会减弱一半，这样通过流式细胞仪检测就可以检测出没有分裂的细胞，分裂一次的细胞(1/2的荧光强度)，分离两次的细胞(1/4的荧光强度)，分裂三次的细胞(1/8的荧光强度)以及类似的其它分裂次数的细胞。

采用CFDA SE 通过流式细胞仪检测获得的检测结果参考右图。

每一个峰代表一种分裂次数的细胞，从右至左的峰通常依次为分裂0次、1次、2次、3次等次数的细胞。

化妆品安全技术规范2015版

化妆品安全技术规范（报送稿）目录正文 (1)1 范围 (1)2术语和释义 (1)3 化妆品安全通用要求 (2)附录一、化妆品禁用组分 (4)表1 化妆品禁用组分(1)(2) (4)表2 化妆品禁用植（动）物组分(1)(2)(3) (95)附录二、化妆品限用组分 (102)表3 限用防腐剂(1) (102)表4 限用防晒剂(1) (109)表5 限用着色剂(1) (113)表6 限用染发剂(1)(3) (4) (136)表7 其他限用组分 (144)附录三、化妆品检测和评价方法 (157)一、理化检验方法 (157)（一）总则 (157)（二）禁用组分 (160)第1节 4-氨基偶氮苯和联苯胺 (160)第2节 4-氨基联苯及其盐 (164)第3节 8-甲氧基补骨脂素等4种物质 (168)第4节α-氯甲苯 (172)第5节氨基己酸 (176)第6节斑蝥素 (179)第7节苯并[а]芘 (181)第8节丙烯酰胺 (184)第9节补骨脂素等4种物质 (188)第10节氮芥 (191)第11节二噁烷 (193)第12节镉 (196)第13节汞 (199)第14节环氧乙烷和甲基环氧乙烷 (204)第15节甲醇 (208)第16节马来酸二乙酯 (211)第17节米诺地尔 (215)第18节铅 (219)第19节氢醌、苯酚 (222)第20节砷 (228)第21节石棉 (234)第22节维甲酸和异维甲酸 (241)第23节维生素D2和维生素D3 (246)（三）限用组分 (249)第1节 6-甲基香豆素 (249)第2节α-羟基酸 (256)第3节二硫化硒 (262)第4节过氧化氢 (265)第5节间苯二酚 (268)第6节可溶性锌盐 (270)第7节奎宁 (272)第8节硼酸和硼酸盐 (274)第9节羟基喹啉 (277)第10节巯基乙酸 (279)第11节水杨酸 (285)第12节酮麝香 (288)第13节游离氢氧化物 (290)第14节总硒 (292)（四）防腐剂 (295)第1节苯甲醇 (295)第2节苯甲酸及其钠盐 (302)第3节苯氧异丙醇 (309)第4节苯扎氯铵 (312)第5节苄索氯铵、劳拉氯铵和西他氯铵 (314)第6节甲醛 (316)第7节甲基氯异噻唑啉酮等12种物质 (322)第8节氯苯甘醚 (325)第9节三氯卡班 (327)第10节山梨酸和脱氢乙酸 (329)（五）防晒剂 (331)第1节苯基苯并咪唑磺酸等15种物质 (331)第2节二苯酮-2 (337)第3节二氧化钛 (340)第4节二乙氨羟苯甲酰基苯甲酸己酯 (342)第5节二乙基己基丁酰胺基三嗪酮 (344)第6节亚苄基樟脑磺酸 (346)第7节氧化锌 (349)（六）着色剂 (351)第1节酸性黄36等5种物质 (351)第2节酸性紫43等7种物质 (357)第3节着色剂CI 16185等10种物质 (360)（七）染发剂 (366)第1节对苯二胺等8种物质 (366)第2节对苯二胺等32种物质 (369)（八）去屑剂 (374)第1节水杨酸等5种物质 (374)（九）抗感染药物 (377)第1节氟康唑等9种物质 (377)第2节盐酸美满霉素等7种物质 (382)第3节依诺沙星等10种物质 (384)（十）激素 (388)第1节雌三醇等7种物质 (388)第2节氢化可的松等7种物质 (397)（十一）有机溶剂 (401)第1节二氯甲烷等15种物质 (401)（十二）其他 (406)第1节二甘醇 (406)第2节化妆品抗UVA能力仪器测定法 (410)第3节邻苯二甲酸二甲酯等10种物质 (412)第4节邻苯二甲酸二丁酯等8种物质 (417)第5节钕等15种元素 (422)第6节 pH值 (425)第7节乙醇胺等5种物质 (427)二、微生物检验方法 (433)（一）总则 (433)（二）菌落总数 (435)（三）耐热大肠菌群 (438)（四）铜绿假单胞菌 (441)（五）金黄色葡萄球菌 (444)（六）霉菌和酵母菌 (447)三、毒理学试验方法 (449)（一）总则 (449)（二）急性经口毒性试验 (450)（三）急性经皮毒性试验 (452)（四）皮肤刺激性/腐蚀性试验 (454)（五）急性眼刺激性/腐蚀性试验 (457)（六）皮肤变态反应试验 (460)（七）皮肤光毒性试验 (464)（八）鼠伤寒沙门氏菌／回复突变试验 (467)（九）体外哺乳动物细胞染色体畸变试验 (474)（十）体外哺乳动物细胞基因突变试验 (477)（十一）哺乳动物骨髓细胞染色体畸变试验 (480)（十二）体内哺乳动物细胞微核试验 (483)（十三）睾丸生殖细胞染色体畸变试验 (486)（十四）亚慢性经口毒性试验 (489)（十五）亚慢性经皮毒性试验 (492)（十六）致畸试验 (495)（十七）慢性毒性/致癌性结合试验 (498)四、人体安全性检验方法 (503)（一）总则 (503)（二）人体皮肤斑贴试验 (504)（三）人体试用试验安全性评价 (507)五、人体功效评价检验方法 (509)（一）总则 (509)（二）防晒化妆品防晒指数（SPF值）测定方法 (510)（三）防晒化妆品防水性能测试方法 (517)（四）防晒化妆品长波紫外线防护指数(PFA值)测定方法 (519)正文1 范围本规范规定了化妆品的安全技术要求，包括通用要求、禁限用组分要求以及检验评价方法等。

硫辛酸注射液联合胰激肽原酶肠溶片对DPN_的临床疗效及生存质量的影响

DOI：10.16658/ki.1672-4062.2024.01.174硫辛酸注射液联合胰激肽原酶肠溶片对DPN的临床疗效及生存质量的影响王莉，朱海峰濉溪县中医医院内分泌科，安徽淮北235100[摘要]目的探讨硫辛酸注射液联合胰激肽原酶肠溶片对2型糖尿病周围神经病变（Diabetic Peripheral Neu⁃ropathy， DPN）患者的临床疗效、生存质量及安全性的影响。

方法选取2021年2月—2022年4月濉溪县中医医院60名DPN患者作为研究对象。

通过随机数表法分为两组，每组30例。

对照组采用常规治疗，观察组在对照组基础上加用硫辛酸注射液和胰激肽原酶肠溶片治疗。

比较两组患者的神经病变评分、神经电生理指标、生存质量评分、安全性指标和不良反应发生率。

结果治疗后，观察组神经病变评分（6.2±0.9）分低于对照组（7.6±1.1）分，差异有统计学意义（t=5.438，P<0.05）；观察组神经电生理指标、生存质量评分、安全性指标均优于对照组，差异有统计学意义（P均<0.05）；两组患者不良反应发生率比较，差异无统计学意义（P>0.05）。

结论硫辛酸注射液联合胰激肽原酶肠溶片对DPN患者有良好的临床疗效，能够改善神经功能、改善神经电生理指标、提高生存质量，且安全性高。

[关键词] 硫辛酸注射液；胰激肽原酶肠溶片；2型糖尿病周围神经病变；临床疗效[中图分类号] R587.2 [文献标识码] A [文章编号] 1672-4062（2024）01（a）-0174-05Effect of Lipoic Acid Injection Combined with Pancreatic Kininogenase Enteric-coated Tablets on Clinical Efficacy and Quality of Survival in DPN WANG Li, ZHU HaifengDepartment of Endocrinology, Suixi County Hospital of Traditional Chinese Medicine, Huaibei, Anhui Province, 235100 China[Abstract] Objective To investigate the effects of lipoic acid injection combined with pancreatic kininogenase enteric-coated tablets on the clinical efficacy, quality of survival and safety of patients with type 2 diabetic peripheral neuropathy (DPN). Methods 60 DPN patients admitted to Suixi County Hospital of Traditional Chinese Medicine from February 2021 to April 2022 were selected as the study objects. They were divided into two groups with 30 cases in each group by random number table method. The control group received conventional treatment, and the observation group was treated with lipoic acid injection and pancreatic kininogenase enteric-coated tablets on the basis of control group. Neuropathy score, neuroelectrophysiological index, quality of life score, safety index and incidence of adverse reactions were compared between the two groups. Results After treatment, the neuropathy score of observation group (6.2±0.9) points was lower than that of control group (7.6±1.1) points, and the difference was statistically significant (t= 5.438, P<0.05). Neuroelectrophysiological indexes, quality of survival scores and safety indexes of the observation group were better than those of the control group, and the differences were statistically significant (all P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05). Conclusion Li⁃[作者简介]王莉（1982-），女，本科，主治医生，研究方向为糖尿病周围神经病变。

IFCC Aspartate Aminotransferase 检测手册说明书

ASTAspartate Aminotransferase IFCCMANUAL RX MONZAINTENDED USEFor the quantitative in vitro determination of AspartateAminotransferase (AST) in serum and plasma. This product is suitable for manual use and on the Rx Monza analyser.Cat. No. AS 1202 R1a. Buffer/Substrate 1 x 70 ml 20 x 2 ml R1b. Enzyme/Coenzyme/ 20 x 2 ml α-oxoglutarate GTIN: 05055273200416AS 1204 R1a. Buffer/Substrate 1 x 105 ml 10 x 10 ml R1b. Enzyme/Coenzyme/ 10 x 10 ml α-oxoglutarate GTIN: 05055273200423AS 1267 R1a. Buffer/Substrate 1 x 105 ml 5 x 20 ml R1b. Enzyme/Coenzyme/ 5 x 20 ml α-oxoglutarate GTIN: 05055273200430AS 2359 R1a. Buffer/Substrate 5 x 100 ml 5 x 100 ml R1b. Enzyme/Coenzyme/ 5 x 100 ml α-oxoglutarate GTIN: 05055273200454UV METHODThis is an optimised standard method according to the concentrations recommended by the IFCC.CLINICAL SIGNIFICANCE (1,2,3,4)The aminotransferases are a group of enzymes that catalyse the inter conversions of amino acids and α-oxoacids by transfer of amino groups. AST (aspartate aminotransferase or glutamate oxaloacetatetransaminase) has been found in the cytoplasm and the mitochondria of cells that have been studied. In cases of mild tissue damage, e.g. liver, the predominant form of serum AST is that from the cytoplasm, with a smaller amount coming from the mitochondria. Severe tissue damage will result in more mitochondrial enzyme being released. Elevated levels of AST can signal myocardial infarction, hepatic disease, muscular dystrophy and organ damage.Although heart muscle is found to have the most activity of the enzyme, significant activity has also been seen in the brain, liver, gastric mucosa, adipose tissue and kidneys of humans.The IFCC has now recommended (1980) standardised procedures for AST determinations including:-1. optimization of substrate concentrations.2. Employment of Tris buffers (instead of phosphate, which has beenshown to inhibit recombination of the apoenzyme with pyridoxal phosphate).3. Pre-incubation of combined buffer and serum to allow sidereactions with NADH to occur. 4. Substrate start (α-oxoglutarate)5. Optional pyridoxal phosphate activation.This is an optimised standard method according to the recommendations of the IFCC.PRINCIPLEα-oxoglutarate reacts with L-aspartate in the presence of AST to form L-glutamate plus oxaloacetate. The indicator reaction utilises the oxaloacetate for a kinetic determination of NADH consumption. AST -oxoglutarate + L-aspartate L-glutamate + oxaloacetate MDH oxaloacetate + NADH + H + L-malate + NAD +SPECIMEN COLLECTION AND PREPARATION (5) Serum:- Use serum free from haemolysis.Plasma:- EDTA or heparin can be used as the anticoagulant.Plasma should be separated from cells within one hour after collection.Specimens should be refrigerated if not used immediately:-Specimens stored longer than 3 days should be frozen at -20︒C.REAGENT COMPOSITIONContents Concentrations in the TestR1a. Buffer/Substrate Tris buffer 80 mmol/l, pH 7.5 L-aspartate 240 mmol/l R1b. Enzyme/Coenzyme/α-oxoglutarate α-oxoglutarate 12 mmol/l MDH ≥420 U/l LD ≥600 U/l NADH 0.18 mmol/lSAFETY PRECAUTIONS AND WARNINGS For in vitro diagnostic use only. Do not pipette by mouth.Exercise the normal precautions required for handling laboratory reagents.Solution R1a contains Sodium Azide. Avoid ingestion or contact with skin or mucous membranes. In case of skin contact, flush affected area with copious amounts of water. In case of contact with eyes or if ingested, seek immediate medical attention.Sodium Azide reacts with lead and copper plumbing, to form potentially explosive azides. When disposing of such reagents flush with large volumes of water to prevent azide build up. Exposed metal surfaces should be cleaned with 10% sodium hydroxide.Health and Safety data sheets available on request.The reagents must be used only for the purpose intended by suitably qualified laboratory personnel, under appropriate laboratory conditions.STABILITY AND PREPARATION OF REAGENTS R1a. Buffer/SubstrateContents ready for use. Stable up to the expiry date when stored at +2 to +8︒C.R1b. Enzyme/Coenzyme/α-oxoglutarate Reconstitute one vial of Enzyme/Coenzyme/α-oxoglutarate R1b with the appropriate volume of Buffer/Substrate R1a: 2 ml for the 20 x 2 ml kit (AS 1202) 10 ml for the 10 x 10 ml kit (AS 1204) 20 ml for the 5 x 20 ml kit (AS 1267) Stable for 14 days at +2 to +8︒C or 24 hours at +15 to +25︒C. Cat. AS 2359 5 x 100 mlReconstitute one vial of Enzyme/Coenzyme/α-oxoglutarate R1b with a portion of Buffer/Substrate R1a and then transfer the entire contents to bottle R1a rinsing bottle R1b several times. Stable for 14 days at +2 to +8︒C or 24 hours at +15 to +25︒C.MATERIALS PROVIDED Buffer/SubstrateEnzyme/Coenzyme/ -oxoglutarateMATERIALS REQUIRED BUT NOT PROVIDEDRandox Assayed Multisera Level 2 (Cat. No. HN 1530) and Level 3 (Cat. No. HE 1532)Randox Calibration Serum Level 3 (Cat. No. CAL 2351) RX series Saline (Cat. No. SA 3854)PROCEDUREAspirate fresh ddH 2O and perform a new Gain Calibration in flow cell mode. Select AST in the Run Test screen and carry out a water blank as instructed.Pipette into a test tube:Sample 0.05 ml Reagent 0.5 mlMix and aspirate into the Rx Monza.CALIBRATION FOR RX MONZAThe use of Saline and Randox Calibration Serum Level 3 isrecommended for calibration. Calibration is recommended with change of reagent lot or as indicated by quality control procedures.FOR MANUAL USEWavelength: 340 nm (Hg 334 nm or Hg 365 nm) Cuvette: 1 cm light path Temperature: 25/30/37︒C Measurement: against airPipette into cuvette: Macro MicroSample 0.2 ml 0.1 ml Enzyme/Coenzyme/ α-oxoglutarate R1 2.0 ml 1.0 mlMix, read initial absorbance after 1 minute. Read again after 1, 2 and 3 minutes. Note: If the absorbance change per minute is between 0.11 and 0.16 at 340/Hg 334 nm 0.06 and 0.08 at Hg 365 nmuse only the values for the first 2 minutes for the calculation.MANUAL CALCULATIONTo calculate the AST activity, use the following formulae:U/l = 1746 x A 340 nm/min U/l = 1780 x A Hg 334 nm/min U/l = 3235 x A Hg 365 nm/minSTANDARDISATIONRandox Calibration Serum Level 3 is traceable to AST reference material JSCC TS01.QUALITY CONTROLRandox Assayed Multisera, Level 2 and Level 3 are recommended for daily quality control. Two levels of controls should be assayed at least once a day. Values obtained should fall within a specified range. If these values fall outside the range and repetition excludes error the following steps should be taken:1. Check instrument settings and light source.2. Check cleanliness of all equipment in use.3. Check water. Contaminants, i.e. bacterial growth, maycontribute to inaccurate results. 4. Check reaction temperature.5. Check expiry date of kit and contents.6. Contact Randox Laboratories Customer Technical Services, Northern Ireland +44 (0) 28 9445 1070.SPECIFICITY/INTERFERENCE (6,7)Gross haemolysis will produce falsely elevated test results. The effects of various drugs on AST activity should be taken intoconsideration in the case of patients receiving large doses of drugs.The analytes below were tested up to the following levels and were found not to interfere: Haemoglobin 250 mg/dl Free Bilirubin 25 mg/dl Conjugate Bilirubin 25 mg/dl Triglycerides 1000 mg/dlIntralipid ® 200 mg/dlA list of substances and conditions known to effect AST activity in vivo is given by both Young et al and Friedman et al. Norepresentation is made by Randox Laboratories Ltd regarding the completeness of these lists and the accuracy of the information contained therein.NORMAL VALUES IN SERUM (8,9) +25︒C +30︒C +37︒C Men up to 18 U/l up to 25 U/l up to 37 U/l Women up to 15 U/l up to 21 U/l up to 31 U/lIt is recommended that each laboratory establish its own reference range to reflect the age, sex, diet and geographical location of the population.SPECIFIC PERFORMANCE CHARACTERISTICS The following performance data were obtained using an Rx Monza analyser running at +37o C.LINEARITYThis method is linear up to 562 U/l. If the sample concentration exceeds this value, dilute the sample 1+9 with 0.9% NaCl solution and re-assay. Multiply the result by 10.SENSITIVITYThe minimum detectable concentration of AST with an acceptable level of precision was determined as 9.3 U/l.PRECISIONIntra AssayLevel 2 Level 3Mean (U/l) 35.6 153SD 1.66 1.47CV(%) 4.65 0.96n 20 20Inter AssayLevel 2 Level 3Mean (U/l) 35.6 153SD 1.77 7.10CV(%) 4.96 4.63n 20 20CORRELATIONThis method (Y) was compared with another commerciallyavailable method (X) and the following linear regression equationobtained:Y = 1.07X + 4.9and a correlation coefficient of r = 0.997543 patient samples were analysed spanning the range 28 to 559U/l.REFERENCES1. Wroblewski F, La Due J.S: Ann Intern Med. 1956; 45: 801.2. Wroblewski F, La Due J.S: Proc Soc Exp Biol Med 1956;91: 569.3. Bergmeyer HU, Bowers GN Jr, et al: Clin Chem 1977; 23:887.4. Bergmeyer HU, Bowers GN Jr, et al: J.Clin Chem ClinBiochem 1980; 18: 521-534.5. Tietz N W: Fundamentals of Clinical Chemistry ed 3.Philadelphia, WB Saunders Co. 1987, pg 372.6. Young D S, et al: Clin Chem 1975, 21; No5.7. Friedman RB, et al: Clin Chem 1980, 26; No4.8. Wallnofer H, Schmidt.E, Schmidt FW, eds: Synopsis derLeberkrankheiten Stuttgart, Georg Thieme Verlag, 1974.9. Thefeld W, et al: Dtsch Med Wschr 1974; 99: 343.Revised 26 Apr 16 biRev. 003THIS PAGE IS INTENTIONALLY BLANK。

-R-GNE-140-SDS-MedChemExpress

Inhibitors, Agonists, Screening LibrariesSafety Data Sheet Revision Date:Oct.-06-2018Print Date:Oct.-06-20181. PRODUCT AND COMPANY IDENTIFICATION1.1 Product identifierProduct name :(R)-GNE-140Catalog No. :HY-100742ACAS No. :2003234-63-51.2 Relevant identified uses of the substance or mixture and uses advised againstIdentified uses :Laboratory chemicals, manufacture of substances.1.3 Details of the supplier of the safety data sheetCompany:MedChemExpress USATel:609-228-6898Fax:609-228-5909E-mail:sales@1.4 Emergency telephone numberEmergency Phone #:609-228-68982. HAZARDS IDENTIFICATION2.1 Classification of the substance or mixtureNot a hazardous substance or mixture.2.2 GHS Label elements, including precautionary statementsNot a hazardous substance or mixture.2.3 Other hazardsNone.3. COMPOSITION/INFORMATION ON INGREDIENTS3.1 SubstancesSynonyms:NoneFormula:C25H23ClN2O3S2Molecular Weight:499.04CAS No. :2003234-63-54. FIRST AID MEASURES4.1 Description of first aid measuresEye contactRemove any contact lenses, locate eye-wash station, and flush eyes immediately with large amounts of water. Separate eyelids with fingers to ensure adequate flushing. Promptly call a physician.Skin contactRinse skin thoroughly with large amounts of water. Remove contaminated clothing and shoes and call a physician.InhalationImmediately relocate self or casualty to fresh air. If breathing is difficult, give cardiopulmonary resuscitation (CPR). Avoid mouth-to-mouth resuscitation.IngestionWash out mouth with water; Do NOT induce vomiting; call a physician.4.2 Most important symptoms and effects, both acute and delayedThe most important known symptoms and effects are described in the labelling (see section 2.2).4.3 Indication of any immediate medical attention and special treatment neededTreat symptomatically.5. FIRE FIGHTING MEASURES5.1 Extinguishing mediaSuitable extinguishing mediaUse water spray, dry chemical, foam, and carbon dioxide fire extinguisher.5.2 Special hazards arising from the substance or mixtureDuring combustion, may emit irritant fumes.5.3 Advice for firefightersWear self-contained breathing apparatus and protective clothing.6. ACCIDENTAL RELEASE MEASURES6.1 Personal precautions, protective equipment and emergency proceduresUse full personal protective equipment. Avoid breathing vapors, mist, dust or gas. Ensure adequate ventilation. Evacuate personnel to safe areas.Refer to protective measures listed in sections 8.6.2 Environmental precautionsTry to prevent further leakage or spillage. Keep the product away from drains or water courses.6.3 Methods and materials for containment and cleaning upAbsorb solutions with finely-powdered liquid-binding material (diatomite, universal binders); Decontaminate surfaces and equipment by scrubbing with alcohol; Dispose of contaminated material according to Section 13.7. HANDLING AND STORAGE7.1 Precautions for safe handlingAvoid inhalation, contact with eyes and skin. Avoid dust and aerosol formation. Use only in areas with appropriate exhaust ventilation.7.2 Conditions for safe storage, including any incompatibilitiesKeep container tightly sealed in cool, well-ventilated area. Keep away from direct sunlight and sources of ignition.Recommended storage temperature:Powder-20°C 3 years4°C 2 yearsIn solvent-80°C 6 months-20°C 1 monthShipping at room temperature if less than 2 weeks.7.3 Specific end use(s)No data available.8. EXPOSURE CONTROLS/PERSONAL PROTECTION8.1 Control parametersComponents with workplace control parametersThis product contains no substances with occupational exposure limit values.8.2 Exposure controlsEngineering controlsEnsure adequate ventilation. Provide accessible safety shower and eye wash station.Personal protective equipmentEye protection Safety goggles with side-shields.Hand protection Protective gloves.Skin and body protection Impervious clothing.Respiratory protection Suitable respirator.Environmental exposure controls Keep the product away from drains, water courses or the soil. Cleanspillages in a safe way as soon as possible.9. PHYSICAL AND CHEMICAL PROPERTIES9.1 Information on basic physical and chemical propertiesAppearance Light yellow to yellow (Solid)Odor No data availableOdor threshold No data availablepH No data availableMelting/freezing point No data availableBoiling point/range No data availableFlash point No data availableEvaporation rate No data availableFlammability (solid, gas)No data availableUpper/lower flammability or explosive limits No data availableVapor pressure No data availableVapor density No data availableRelative density No data availableWater Solubility No data availablePartition coefficient No data availableAuto-ignition temperature No data availableDecomposition temperature No data availableViscosity No data availableExplosive properties No data availableOxidizing properties No data available9.2 Other safety informationNo data available.10. STABILITY AND REACTIVITY10.1 ReactivityNo data available.10.2 Chemical stabilityStable under recommended storage conditions.10.3 Possibility of hazardous reactionsNo data available.10.4 Conditions to avoidNo data available.10.5 Incompatible materialsStrong acids/alkalis, strong oxidising/reducing agents.10.6 Hazardous decomposition productsUnder fire conditions, may decompose and emit toxic fumes.Other decomposition products - no data available.11.TOXICOLOGICAL INFORMATION11.1 Information on toxicological effectsAcute toxicityClassified based on available data. For more details, see section 2Skin corrosion/irritationClassified based on available data. For more details, see section 2Serious eye damage/irritationClassified based on available data. For more details, see section 2Respiratory or skin sensitizationClassified based on available data. For more details, see section 2Germ cell mutagenicityClassified based on available data. For more details, see section 2CarcinogenicityIARC: No component of this product present at a level equal to or greater than 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.ACGIH: No component of this product present at a level equal to or greater than 0.1% is identified as a potential or confirmed carcinogen by ACGIH.NTP: No component of this product present at a level equal to or greater than 0.1% is identified as a anticipated or confirmed carcinogen by NTP.OSHA: No component of this product present at a level equal to or greater than 0.1% is identified as a potential or confirmed carcinogen by OSHA.Reproductive toxicityClassified based on available data. For more details, see section 2Specific target organ toxicity - single exposureClassified based on available data. For more details, see section 2Specific target organ toxicity - repeated exposureClassified based on available data. For more details, see section 2Aspiration hazardClassified based on available data. For more details, see section 212. ECOLOGICAL INFORMATION12.1 ToxicityNo data available.12.2 Persistence and degradabilityNo data available.12.3 Bioaccumlative potentialNo data available.12.4 Mobility in soilNo data available.12.5 Results of PBT and vPvB assessmentPBT/vPvB assessment unavailable as chemical safety assessment not required or not conducted.12.6 Other adverse effectsNo data available.13. DISPOSAL CONSIDERATIONS13.1 Waste treatment methodsProductDispose substance in accordance with prevailing country, federal, state and local regulations.Contaminated packagingConduct recycling or disposal in accordance with prevailing country, federal, state and local regulations.14. TRANSPORT INFORMATIONDOT (US)This substance is considered to be non-hazardous for transport.IMDGThis substance is considered to be non-hazardous for transport.IATAThis substance is considered to be non-hazardous for transport.15. REGULATORY INFORMATIONSARA 302 Components:No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302.SARA 313 Components:This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.SARA 311/312 Hazards:No SARA Hazards.Massachusetts Right To Know Components:No components are subject to the Massachusetts Right to Know Act.Pennsylvania Right To Know Components:No components are subject to the Pennsylvania Right to Know Act.New Jersey Right To Know Components:No components are subject to the New Jersey Right to Know Act.California Prop. 65 Components:This product does not contain any chemicals known to State of California to cause cancer, birth defects, or anyother reproductive harm.16. OTHER INFORMATIONCopyright 2018 MedChemExpress. The above information is correct to the best of our present knowledge but does not purport to be all inclusive and should be used only as a guide. The product is for research use only and for experienced personnel. It must only be handled by suitably qualified experienced scientists in appropriately equipped and authorized facilities. The burden of safe use of this material rests entirely with the user. MedChemExpress disclaims all liability for any damage resulting from handling or from contact with this product.Caution: Product has not been fully validated for medical applications. For research use only.Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA。

基于QuEChERS-液相色谱-串联质谱法测定纸制品中4种异噻唑啉酮类杀菌剂

广东化工2021年第10期· 214· 第48卷总第444期基于QuEChERS-液相色谱-串联质谱法测定纸制品中4种异噻唑啉酮类杀菌剂李柏，陈山丹，冯杰，刘萍，钱志娟(南京海关轻工产品与儿童用品检测中心，江苏扬州225009)[摘要]建立了QuEChERS结合液相色谱-串联质谱法测定纸制品中4种异噻唑啉酮杀菌剂(MI，CMI，OI和BIT)的含量。

采用多反应监测模式进行定性，外标法定量。

结果表明在5~250 μg/L(OI为0.5~25 μg/L)范围内线性关系良好(R2=0.9986~0.9999)。

方法的检出限LOD为0.044~0.571μg/L，定量限LOQ为0.146~1.91 μg/L。

4种不同的纸制品在0.2，2.5和4.0 mg/kg三个添加水平的加标回收率为84.4%~101.4%，相对标准偏差(RSD%)为2.11%~7.82%。

该方法快速，灵敏，能够满足纸制品中异噻唑啉酮杀菌剂的检测要求。

[关键词]QuEChERS；液相色谱-串联质谱，异噻唑啉酮，纸制品[中图分类号]TQ [文献标识码]A[文章编号]1007-1865(2021)10-0214-03Determination of Four Isothiazolinone Biocides in Paper Products byQuEChERS-liquid Chromatography-tandem Mass SpectrometryLi Bai, Chen Shandan,Feng Jie,Liu Ping, Qian Zhijuan(Nanjing Customs District Light Industry Products and Children’s Products Inspection Center, Yangzhou 225009, China) Abstract: A method was developed for the determination of four isothiazolinone biocides in paper products by QuEChERS with liquid chromatography-tandem mass spectrometry. The multi reaction monitoring model was used for qualitative analysis and the external standard method was used for quantitative analysis.These 4 biocides showed a good linearity in the range of 5~250 μg/L(OI in the range of 0.5~25 μg/L)(R2=0.9986~0.9999).The limit of detection (LOD) was0.044~0.571 μg/L and limit of quantitation (LOQ) was 0.146~1.91 μg/L.The average recoveries of 4 biocides were in the range of 84.4%~101.4% at the three spiked levels (0.2, 2.5 and 4.0 mg/kg) in the four different paper products and the RSD% was in the range of 2.11%~7.82%. The method is rapid, sensitive and can meet the requirements of the detection of isothiazolinone biocides in paper products.Keywords: QuEChERS；Liquid chromatography-tandem mass spectrometry；isothiazolinone；paper products在造纸工业中，造纸原料和水源中不可避免存在着大量的微生物如霉菌、细菌等，更会在各个工艺流程的环节也残留着微生物。

石油醚化学品安全技术说明书

化学品安全技术说明书产品名称: 石油醚按照GB/T 16483、GB/T 17519 编制修订日期: 2019年7月15日版本: 1.0最初编制日期: 2019年7月15日第1部分化学品及企业标识化学品中文名：石油醚化学品英文名： Ligroine产品编号： -企业名称：上海百舜生物科技有限公司企业地址：上海奉贤区柘林镇联业路918弄26号邮编： 201400传真：联系电话：电子邮件地址：企业应急电话：产品推荐及限制用途：工业及科研用途。

第2部分危险性概述紧急情况概述：吞咽并进入呼吸道可能致命。

可能导致遗传性缺陷。

可能致癌。

GHS危险性类别：吸入危害类别 1生殖细胞致突变性类别 1B致癌性类别 1B标签要素：象形图：警示词：危险危险性说明：H304 吞咽并进入呼吸道可能致命H340 可能导致遗传性缺陷H350 可能致癌防范说明：预防措施：—— P201 使用前取得专用说明。

—— P202 在阅读并明了所有安全措施前切勿搬动。

—— P280 戴防护手套/穿防护服/戴防护眼罩/戴防护面具。

事故响应：—— P301+P310 如误吞咽：立即呼叫解毒中心/医生—— P331 不得诱导呕吐。

—— P308+P313 如接触到或有疑虑：求医/就诊。

安全储存：—— P405 存放处须加锁。

废弃处置：—— P501 按当地法规处置内装物/容器。

物理和化学危险：无资料健康危害：吞咽并进入呼吸道可能致命。

可能导致遗传性缺陷。

可能致癌。

环境危害：无资料第3部分成分/组成信息组分浓度或浓度范围(质量分数，%)CAS No.Ligroine100%8032-32-4第4部分急救措施急救：吸入：迅速脱离现场至空气新鲜处。

保持呼吸道通畅。

如呼吸困难，给输氧。

呼吸、心跳停止，立即进行心肺复苏术。

就医皮肤接触：立即脱去污染的衣着，用肥皂水和清水彻底冲洗。

就医眼晴接触：立即分开眼睑，用流动清水或生理盐水彻底冲洗。

就医食入：潄口，不要催吐。

Eastep

技术手册V3.7Eastep ® Super 总RNA 提取试剂盒 (Eastep ® Super Total RNA Extraction Kit) 产品目录号：LS1040上海普洛麦格生物产品有限公司目录◼产品描述 (1)◼试剂盒组分 (1)◼存储条件 (1)◼试剂配制 (2)◼预防RNase污染的注意事项 (2)◼不同细胞的破碎方法 (2)◼不同样品起始用量 (3)◼RNA分离纯化流程图 (4)◼从动物组织中提取RNA (5)◼从贴壁或悬浮细胞中提取RNA (6)◼从植物组织中提取RNA (8)◼从革兰氏阳性（枯草杆菌）和革兰氏阴性（大肠杆菌）细菌中提取RNA (10)◼不同材料提取RNA的得率 (11)◼问题及解决办法 (12)◼附录 (14)1.PBS缓冲液，(10×)，pH 7.4 (14)2.胰蛋白酶-EDTA溶液(1×) (14)3.1×TE缓冲液，pH 8.0 (14)◼产品描述RNA的纯度和完整性在RT-PCR、qRT-PCR、RNase保护、Northern Blot、体外翻译和微阵列分析等分子生物学实验中至关重要。

近年来，RT-PCR和qRT-PCR已经演变成定性、定量分析某些特定mRNA的有力工具。

随着基因扩增技术的不断成熟，从组织、培养细胞等小量样本中快速纯化得到无基因组DNA污染的高质量RNA的需求越来越迫切，Eastep® Super总RNA提取试剂盒也因此应运而生。

Eastep® Super总RNA提取试剂盒（LS1040）为客户提供了一套从动物组织、植物组织、培养细胞、细菌中小量纯化高质量、完整总RNA的解决方案。

该试剂盒采用独特的细胞裂解系统，无需使用苯酚、氯仿等有害物质，通过离心柱硅基质膜高效、专一地吸附核酸分子，再经DNA酶处理去除基因组DNA的污染，最终得到高纯度的总RNA。

本产品具有高效、快速、方便之特点，单个样品提取纯化一般可在30分钟内完成。

乙酰胆碱酯酶抑制剂

上海应用技术学院研究生课程《高等天然产物化学》试卷2014 / 2015 学年第1 学期课程代码：NX0702013论文题目：乙酰胆碱酯酶抑制剂的研究进展姓名：芮银146061414康满满146061409专业：制药工程学院：化工学院乙酰胆碱酯酶抑制剂的研究进展芮银，陈祎桐，康满满摘要：本文阐述了乙酰胆碱酯酶抑制剂(AChEI)的研究进展，介绍了用于药物治疗的乙酰胆碱酯酶抑制剂的各种来源如植物、微生物等，及其抑制乙酰胆碱的活性物质。

在此基础上，总结了几种现代分析技术，对AChEIs进行筛选，大大加快AD药物资源的开发利用进程。

这些方法主要有基于比色法的Ellman's法及相关的改进方法、薄层显色法、荧光显色法、电喷雾质谱法等。

但是，到目前为止，现代分析技术在AD药物资源中的应用还处在起步阶段。

关键词：乙酰胆碱酯酶抑制剂，筛选方法，薄层显色法，荧光显色法The progress of acetylcholinesteraseinhibitorsRui Yin, Chen Yitong, Kang ManmanAbstract：In this artical, the research elaborates progress of acetylcholinesterase inhibitors (AChEI), and introduces a variety of sources for drug treatment acetylcholinesterase inhibitors such as plants, microorganisms, and its active ingredients. On this basis, the review summarizes several modern analytic techniques such as Ellman's method which based on the colorimetric method, TLC chromogenic method, fluorescent color method, Electrospray ionization mass spectrometry and so on. However, at present, the application of modern analytic techniques in AD drug resources is still in infancy.Key word: Acetylcholinesterase inhibitors, Screening Methods, TLC chromogenic method, Fluorescent color method目录摘要.................................................................................................错误!未定义书签。

石榴花水提物调节AHR

叶雨萌，荣雨，李包娟，等. 石榴花水提物调节AHR/BNIP3改善糖尿病小鼠肝脏胰岛素信号[J]. 食品工业科技，2024，45（7）：320−327. doi: 10.13386/j.issn1002-0306.2023100075YE Yumeng, RONG Yu, LI Baojuan, et al. Pomegranate Flower Water Extract Modulates AHR/BNIP3 to Improve Hepatic Insulin Signaling in Diabetic Mice[J]. Science and Technology of Food Industry, 2024, 45(7): 320−327. (in Chinese with English abstract). doi:10.13386/j.issn1002-0306.2023100075· 营养与保健 ·石榴花水提物调节AHR/BNIP3改善糖尿病小鼠肝脏胰岛素信号叶雨萌，荣　雨，李包娟，周克春，张䶮之*（新疆医科大学药学院，新疆乌鲁木齐 830000）摘　要：目的：探讨石榴花水提物（pomegranate flower water extract ，PFW ）对2型糖尿病小鼠肝脏胰岛素信号传导的影响及机制。

方法：将C57BL/6J 随机分为正常组、模型组、二甲双胍组（Met ）、石榴花水提物低剂量组（PFWL ）和石榴花水提物高剂量组（PFWH ）。

连续给药11周后，称小鼠体质量，检测空腹血糖（FBG ）、胰岛素（INS ）、甘油三酯（TG ）和总胆固醇（TC ）的含量，计算胰岛素抵抗指数（HOMA-IR ）；苏木素-伊红（HE ）染色观察肝组织病理变化；Western blot 法检测肝组织中胰岛素受体底物1（IRS1）、p-IRS1（Ser307）、蛋白激酶B （AKT ）、p-AKT （Ser473）、糖原合成酶激酶-3β（Gsk3β）、p-Gsk3β（S9）、芳香烃受体（AhR ）、磷脂酰乙醇胺N-甲基转移酶（PEMT ）、Bcl-2/腺病毒E1B-19kDa 相互作用蛋白3（BNIP3）蛋白表达。

Lomustine_13010-47-4_DataSheet_MedChemExpress

Product Name:Lomustine CAS No.:13010-47-4Product Data SheetCat. No.:HY-13669MWt:233.70Formula:C9H16ClN3O2Purity :>98%Solubility:Mechanisms:Biological Activity:Pathways:Cell Cycle/DNA Damage; Target:DNA Alkylating 25°C: DMSO 47 mg/mL; Water <1mg/mL; Ethanol 47 mg/mLg yDescription:IC50 Value: N/A Lomustine (or "CCNU")(Marketed under the name CeeNU in US) is an alkylating nitrosoureacompound used in chemotherapy. in vitro: vincristine and lomustine trigger apoptosis in all these cells through the mitochondrial pathway via decrease in the level of the anti-apoptosis proteins Bcl-2 and Bcl-xl, respectively [1].There was significant correlation between the level of cadherin-associated protein beta 1 (CTNNB1)and Aurora kinase A (STK15) proteins and neurotrophic tyrosine kinase receptor type 3 (TRKC)References:[1]. Shinwari Z, Manogaran PS, Alrokayan SA, Vincristine and lomustine induce apoptosis and p21(WAF1) up-regulation in medulloblastoma and normal human epithelial and fibroblast cells. JNeurooncol. 2008 Apr;87(2):123-32. Epub 2007 Dec 6.[2]. Bethune C, Blum A, Geyer JR, Lipid association increases the potency against primary ()p p y p yp ()mRNA and the proportion of apoptosis induced by vincristine, the combination of both drugs, andlomustine, respectively [4].in vivo:IC50values for CCNU admixed and encapsulated with lipid vesicles were 18+/-49and []y p p y g p y medulloblastoma cells and systemic exposure of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea(CCNU) in rats. Pharm Res. 1999 Jun;16(6):896-903.[3]. Rassnick KM, Moore AS, Williams LE, Treatment of canine mast cell tumors with CCNU(lomustine). J Vet Intern Med. 1999 Nov-Dec;13(6):601-5.[4]. Shinwari Z, Al-Hindi H, Al-Shail E, Response of medulloblastoma cells to vincristine and lomustine: role of TRKC, CTNNB1 and STK15. Anticancer Res. 2011 May;31(5):1721-33....Caution: Not fully tested. For research purposes onlyMedchemexpress LLC18W i l k i n s o n W a y , P r i n c e t o n , N J 08540,U S AE m a i l : i n f o @m e d c h e m e x p r e s s .c o m W e b : w w w .m e d c h e m e x p r e s s .c om。

罗氏电化学发光

80~120T/h 60~90T/h 一次60~90个,随时添加 30,66,75个不等 20个,随时添加 6,15个,不可添加可随时添加有条件限制
AxSYM与Elecsys主要性能比较
AxSYM
反应区每个测试独立反应区
Elecsys
流动池结构
优势
试剂混匀方式试剂稳定性定标周期标准品质控灵敏度(TSH) 精密度携带率
自动转测有第一出结果时间 8分钟吸样方式探针组合配套有,随意无限触摸屏有试剂盒自动开盖有试剂条码标准曲线数有,一维,可手工输入 4条不同批号曲线
雅培与罗氏肝炎试剂比较(1)
雅培罗氏
种类
定量项目检测步骤
甲,乙,丙肝炎
HAV-IgG,AUSAB,HBe 一步法(HAV,CORE),二步法 (HBsAg,AUSAB,HBe, Anti-HBe, HCV)三步法(HAV-IgM,CORE-M)
ECL检测技术原理
二价的三联吡啶钌在电场的作用下,失去一个电子氧
化成三价的三联吡啶钌
同时,在电场作用下,三丙胺也失去一个电子被氧化,
然后脱氢成三丙胺自由基
三丙胺自由基传递一个电子给三价的三联吡啶钌使
之进入激发态
激发态的三联吡啶钌不稳定,以发射一个波长为
620nm的光子的形式释放能量而回到基态三联吡啶钌不被消耗,即发光标记物可循环发光
Elecsys 2010系统浏览
ห้องสมุดไป่ตู้试剂样品探针,使用一次性 Tip头,一个测试2~3只,仍需蒸溜水请洗
混匀搅拌棒,蒸溜水清洗
Elecsys 2010系统浏览
•反应杯架:60X3(最多5架) •Tip头架:120X3(最多5架) •孵育架:32个位置(有限) •机械抓手,容易机械故障

Lomustine_13010-47-4_DataSheet_MedChemExpress

Naglazyme（galsulfase）（抗生物）商品说明书

HSF1A_DataSheet_MedChemExpress

ACCUSPIN系统-Histopaque 1077产品说明书

3_种常用碳青霉烯类抗生素血药浓度UPLC-MS

CFDA SE (细胞增殖示踪荧光探针) 说明书

化妆品安全技术规范2015版

硫辛酸注射液联合胰激肽原酶肠溶片对DPN_的临床疗效及生存质量的影响

IFCC Aspartate Aminotransferase 检测手册说明书

-R-GNE-140-SDS-MedChemExpress

基于QuEChERS-液相色谱-串联质谱法测定纸制品中4种异噻唑啉酮类杀菌剂

石油醚 化学品安全技术说明书

Eastep

乙酰胆碱酯酶抑制剂

石榴花水提物调节AHR

Lomustine_13010-47-4_DataSheet_MedChemExpress

罗氏电化学发光

石油醚化学品安全技术说明书